India is the pharmacy of the world. But we are losing the drug development race
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
The article argues that despite India being the 'pharmacy of the world' due to its leadership in generic drug manufacturing, it is severely lagging in the high-value area of novel drug development. The primary cause identified is the significant delay in the regulatory approval process for clinical trials, managed by the Central Drugs Standard Control Organisation (CDSCO). This bottleneck stifles innovation and makes India uncompetitive compared to the US and China, which have much faster approval mechanisms.
UPSC Perspectives
Governance & Regulatory Framework
The core issue highlighted is a regulatory bottleneck within India's drug approval system. The current framework is centralized under the , which is the national authority established under the . While the stipulate approval timelines of 90 days (for foreign-developed drugs) and 30 days (for Indian-developed drugs), the article contends that practical delays stretch up to two years. This is attributed to the centralized Subject Expert Committees (SECs) that advise the but are overburdened. The proposed solution is a governance reform towards decentralization and regulatory agility. The article suggests empowering accredited institutions (hospitals, universities, research bodies like ) to form their own SECs to approve early-phase trials. This mirrors the successful Australian model where institutional ethics committees (HRECs) are the primary approvers, and the regulator is simply notified. For UPSC, this raises questions about balancing ease of doing business with patient safety, and whether a decentralized system can maintain uniform standards without compromising on rigorous oversight.
Economic & Industrial Policy
This topic is crucial for understanding India's position in the global pharmaceutical value chain. India excels at the high-volume, low-margin manufacturing of generic drugs but fails to capture the high-margin, high-value segment of novel drug research and development (R&D). The article illustrates this by noting that the revenue of a single US pharma company, Merck, surpasses that of India's entire pharmaceutical industry. This indicates a failure to move up the value chain, which is a key goal of industrial policy. The government has launched initiatives like the [Biopharma SHAKTI] scheme to bolster domestic R&D, manufacturing of complex biologics, and clinical research infrastructure. This scheme also includes provisions to strengthen to align with global timelines. However, the article posits that merely strengthening the existing centralized structure is insufficient. The economic argument is that without fundamental procedural reform to eliminate the approval bottleneck, financial incentives and infrastructure development alone cannot unlock India's potential to become a true leader in drug innovation, thereby losing out on significant economic growth and export opportunities.
Science, Technology & Health Security
The article connects the regulatory lag to India's ability to capitalize on the ongoing biotech revolution, which is increasingly driven by Artificial Intelligence (AI). While India possesses strong talent pools in both computer science and biologics, the administrative bottleneck prevents this human capital from being effectively utilized in the fast-paced field of AI-driven drug discovery. The innovation cycle is broken if a drug designed in months by AI has to wait years for trial approval. This has serious implications for India's health security and self-reliance (Atmanirbhar Bharat). Dependence on Western and Chinese firms for new medicines creates vulnerabilities related to prohibitive costs, intellectual property barriers, and geopolitical supply chain risks. Furthermore, it leads to the neglect of diseases of strategic importance to India, such as adult TB and certain cancers, which are not a priority for global pharmaceutical companies. Fostering a domestic R&D ecosystem, enabled by efficient regulation, is thus not just an economic goal but a critical component of national public health and security strategy.